Vertex EVP sells 2,437 shares under 10b5-1 plan

Vertex Pharmaceuticals executive reports planned share sale Vertex Pharmaceuticals EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares of common stock in an open-market transaction at $475.30 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive reports planned share sale

Vertex Pharmaceuticals EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares of common stock in an open-market transaction at $475.30 per share. After this sale, he directly holds 15,122 shares. The trade was made under a company-approved Rule 10b5-1 trading plan entered into on 11/25/2025.

Insider Trade Summary

Net Seller: 2,437 shares

Net Sell 1 txn

Insider McKechnie Duncan

Role EVP, Chief Commercial Officer

Sold 2,437 shs ($1.16M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,437	$475.30	$1.16M

Holdings After Transaction: Common Stock — 15,122 shares (Direct)

Footnotes (1)

F1. Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) report for Duncan McKechnie?

Vertex reported that EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares of common stock. The sale was an open-market transaction executed at $475.30 per share under a pre-arranged Rule 10b5-1 trading plan.

How many Vertex (VRTX) shares did Duncan McKechnie sell and at what price?

Duncan McKechnie sold 2,437 Vertex common shares at $475.30 per share. This open-market sale was disclosed in a Form 4 filing and was made pursuant to a company-approved Rule 10b5-1 trading plan.

How many Vertex (VRTX) shares does Duncan McKechnie own after the reported sale?

After the reported sale, Duncan McKechnie directly owns 15,122 shares of Vertex common stock. This post-transaction holding reflects the Form 4 disclosure following his 2,437-share open-market sale at $475.30 per share.

Was the Vertex (VRTX) insider sale by Duncan McKechnie under a Rule 10b5-1 plan?

Yes. The Form 4 notes that Duncan McKechnie’s sale was made under a company-approved Rule 10b5-1 trading plan. The plan was entered into on 11/25/2025, providing a preset framework for executing the transaction.

What role does Duncan McKechnie hold at Vertex (VRTX) in this Form 4?

In this Form 4, Duncan McKechnie is identified as Vertex’s Executive Vice President and Chief Commercial Officer. His reported transaction involves a direct holding of common stock and an open-market sale executed under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/06/2026 - 04:05 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKechnie Duncan

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/04/2026		S⁽¹⁾		2,437	D	$475.3	15,122	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR